During this unique time our nation is experiencing, Myriad is dedicated to finding solutions to ensure that patient care is not interrupted. Dr. Thomas Slavin, Senior Vice President of Medical Affairs for Myriad Oncology, provides more insight into what Myriad is offering to streamline the genetic testing process for providers. Our lifetime commitment to patients does not – and will not – change during this challenging time. #workingtogether #wearemyriad

New Guidelines from AUA and ASTRO Support Inclusion of Genomic Testing in Localized Prostate Cancer

New Guidelines from AUA and ASTRO Support Inclusion of Genomic Testing in Localized Prostate Cancer